Breaking News Instant updates and real-time market news.

AKAM

Akamai

$67.94

-3.24 (-4.55%)

, NUS

Nu Skin

$45.20

-4.15 (-8.41%)

10:20
03/25/19
03/25
10:20
03/25/19
10:20

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Akamai (AKAM) downgraded to Sell from Hold at Deutsche Bank with analyst Vijay Bhagavath saying his estimates for fiscal 2019 through fiscal 2021 are below consensus for both sales and earnings. 2. Nu Skin (NUS) downgraded to Sell from Hold at Stifel with analyst Mark Astrachan saying he sees increasing uncertainty surrounding direct selling companies in China relating to the investigation announced in January into the unlawful promotion and sale of health products. 3. TrueCar (TRUE) downgraded to Hold from Buy at Benchmark with analyst Daniel Kurnos saying he believes it may take several quarters for management to regain credibility, with each quarter heavily scrutinized along the way. 4. Texas Instruments (TXN) and Analog Devices (ADI) downgraded to Market Perform from Outperform at Bernstein. 5. CalAmp (CAMP) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying he sees limited catalysts for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

AKAM

Akamai

$67.94

-3.24 (-4.55%)

NUS

Nu Skin

$45.20

-4.15 (-8.41%)

TRUE

TrueCar

$6.25

-0.28 (-4.29%)

TXN

Texas Instruments

$107.33

-2.18 (-1.99%)

ADI

Analog Devices

$104.48

-2.86 (-2.66%)

CAMP

CalAmp

$12.25

-0.03 (-0.24%)

  • 09

    Apr

  • 25

    Apr

  • 28

    May

AKAM Akamai
$67.94

-3.24 (-4.55%)

03/25/19
DBAB
03/25/19
DOWNGRADE
Target $58
DBAB
Sell
Deutsche Bank downgrades Akamai to Sell, sees 20% share downside
Deutsche Bank analyst Vijay Bhagavath downgraded Akamai Technologies to Sell from Hold and lowered his price target for the shares to $58 from $64. The analyst's estimates for fiscal 2019 through fiscal 2021 are below consensus for both sales and earnings. He's calling for 20% downside to current share levels. While Bhagavath sees little risk to March quarter expectations, he sees an "in line to light" sales outlook for the June quarter for Akamai. His downgrade to Sell is based on fundamentals.
03/25/19
DBAB
03/25/19
DOWNGRADE
Target $58
DBAB
Sell
Akamai downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath downgraded Akamai Technologies to Sell from Hold and lowered his price target for the shares to $58 from $64.
03/21/19
EVER
03/21/19
INITIATION
Target $70
EVER
In Line
Akamai initiated with an In Line, valuation fair, says Evercore ISI
As previously reported, Evercore ISI initiated Akamai with an In Line and $70 price target. Analyst Ken Talanian believes new business for the year could slow and views shares as fairly valued.
03/21/19
EVER
03/21/19
INITIATION
Target $70
EVER
In Line
Akamai initiated with an In Line at Evercore ISI
Evercore analyst Ken Talanian initiated Akamai with an In Line and $70 price target.
NUS Nu Skin
$45.20

-4.15 (-8.41%)

10/10/18
10/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Take-Two (TTWO) initiated with an Outperform at Bernstein. 2. Shake Shack (SHAK) initiated with a Hold at Stifel. 3. Nu Skin (NUS) initiated with a Buy at DA Davidson. 4. Micron (MU) initiated with a Neutral at Piper Jaffray. 5. Crispr Therapeutics (CRSP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/18
DADA
12/12/18
NO CHANGE
Target $88
DADA
Buy
Nu Skin price target lowered to $88 from $92 at DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target on Nu Skin to $88 after meeting with its CFO Mark Lawrence in a Holiday Beauty Bus Tour. The analyst states that while he was upbeat about the company's 3-pillar growth strategy around "Platforms, Products, and Programs", her lower price target is driven by the assumption of lower 2019 gross margins as the company's "lower margin manufacturing operations are likely to grow faster than the overall business". Weiser also lowers her FY19 EPS view by 15c to $4.00 but maintains a Buy rating on Nu Skin shares longer term on expectations that the company will gradually phase out its "limited time offers", thereby reducing the lumpiness of its sales growth rate.
11/21/18
TIGR
11/21/18
NO CHANGE
TIGR
Strong Buy
Nu Skin pullback a buying opportunity, says Tigress Financial
Tigress Financial analyst Ivan Feinseth said he views the recent pullback in shares of Nu Skin as a buying opportunity, citing his belief that the company will continue to benefit from the growing global trend of entrepreneurialism and the global aging population. He reiterates his Strong Buy rating on Nu Skin shares.
03/25/19
STFL
03/25/19
DOWNGRADE
Target $43
STFL
Sell
Nu Skin downgraded to Sell from Hold at Stifel
Stifel analyst Mark Astrachan downgraded Nu Skin Enterprises to Sell from Hold and cut his price target for the shares to $43 from $63. The analyst sees increasing uncertainty surrounding direct selling companies in China relating to the investigation announced in January into the unlawful promotion and sale of health products. Further, the recent death of a Nu Skin registered customer who refused medical treatment believing company products would treat illness resulted in the company being cited in two communist party publications, Beijing Youth Daily and China Daily, with the latter calling for an investigation into the woman's death and Nu Skin's misleading advertising, Astrachan tells investors in a research note. The analyst admits he's unable to determine whether an investigation will be undertaken, but he says the mention in prominent party publications is reminiscent of events in 2014 that ultimately resulted in Nu Skin suspending meetings and recruitment, resulting in sales declines for two years in China. Astrachan cites increasing regulatory concerns in China for his downgrade of Nu Skin shares to Sell.
TRUE TrueCar
$6.25

-0.28 (-4.29%)

03/25/19
BNCH
03/25/19
DOWNGRADE
BNCH
Hold
TrueCar downgraded to Hold from Buy at Benchmark
03/25/19
BNCH
03/25/19
DOWNGRADE
BNCH
Hold
TrueCar downgraded to Hold on management credibility issues at Benchmark
As previously reported, Benchmark analyst Daniel Kurnos downgraded TrueCar to Hold from Buy, stating that he believes it may take several quarters for management to regain credibility, with each quarter heavily scrutinized along the way. Kurnos said his rating change is "not a call on any expected further near-term deterioration in operating trends," though he is not anticipating "some miraculous turnaround either."
03/18/19
GSCO
03/18/19
INITIATION
Target $6
GSCO
Sell
TrueCar assumed with a Sell at Goldman Sachs
Goldman Sachs analyst Daniel Powell assumed coverage of TrueCar from analyst Heath Terry and maintained a Sell rating on the shares. He reduced the stock's price target to $6 from $7. Google search updates negatively impacted traffic growth in Q4 and the company expects continued pressure on traffic as it works to adjust its landing pages and user interface to adapt, Powell tells investors in a research note. The implications of slower spend growth amid structural challenges in traffic acquisition could disrupt long-term growth, Powell tells investors in a research note.
02/15/19
CHLM
02/15/19
DOWNGRADE
Target $10
CHLM
Hold
TrueCar downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Steve Dyer downgraded TrueCar to Hold from Buy and lowered his price target to $10 from $14 following weak results and guidance. In a research note to investors, Dyer says he remains optimistic on the company's product pipeline and long-term stock opportunity, but he thinks shares will be range bound for the next several quarters as near-term challenges and limited visibility will be an overhang on shares. Dyer thinks 2019 will be another year of product development and execution, and the fundamental inflection with revenue growth reacceleration and meaningful margin expansion is likely a 2020 event.
TXN Texas Instruments
$107.33

-2.18 (-1.99%)

02/21/19
DZBN
02/21/19
DOWNGRADE
DZBN
Sell
Texas Instruments downgraded to Sell from Hold at DZ Bank
03/25/19
BERN
03/25/19
DOWNGRADE
BERN
Market Perform
Texas Instruments downgraded to Market Perform from Outperform at Bernstein
03/25/19
BERN
03/25/19
DOWNGRADE
Target $115
BERN
Market Perform
Texas Instruments downgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst Stacy Rasgon downgraded Texas Instruments to Market Perform from Outperform, with a $115 price target, after the shares recent run. While the analyst would not "talk anyone out of owning" shares for the long-term, given the broader set-up he might prefer to put new money to work in other parts of the space with more valuation support. Rasgon acknowledges that Texas Instruments' numbers are "unaggressive," though he does see some potential for a bit of gross margin headwinds. Overall, the analyst believes the shares appear "reasonably fairly valued" at this point.
02/21/19
BMOC
02/21/19
NO CHANGE
Target $130
BMOC
Outperform
Analog Devices price target raised to $130 from $107 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Analog Devices (ADI) to $130 and kept his Outperform rating after its better than expected Q1 results, also citing the company's increase in target dividend growth rate. The analyst sees the company, along with Texas Instruments (TXN), as a powerhouse in the "still fragmented analog market" and expects both to get even stronger. Srivastava also raises his FY19 EPS view for Analog Devices to $5.61 from $5.56 and FY20 view to $6.10 from $5.93.
ADI Analog Devices
$104.48

-2.86 (-2.66%)

03/25/19
BERN
03/25/19
DOWNGRADE
BERN
Market Perform
Analog Devices downgraded to Market Perform from Outperform at Bernstein
02/21/19
RHCO
02/21/19
NO CHANGE
Target $126
RHCO
Buy
Analog Devices price target raised to $126 from $106 at SunTrust
SunTrust analyst William Stein raised his price target on Analog Devices to $126 and kept his Buy rating after its Q4 earnings beat, saying the company's investments are bearing fruit even though the progress in U.S.-China trade talks remains the "biggest swing factor". The analyst adds that his new price target on Analog Devices is driven by his rolled out FY20 estimates, which assume a 21-times expected earnings multiple - still a 1-turn discount to its higher peer group average multiple.
03/25/19
03/25/19
DOWNGRADE
Target $120

Market Perform
Analog Devices downgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst Stacy Rasgon downgraded Analog Devices to Market Perform from Outperform, with a $120 price target, after the shares recent run. While the analyst would not "talk anyone out of owning" shares for the long-term, given the broader set-up he might prefer to put new money to work in other parts of the space with more valuation support. Further, the analyst notes that his original Analog Devices upgrade a year ago was based on valuation renormalization, which has now occurred. While the company may be able to grind some more growth out of the communications story it seems to be expected at this point, he contends.
CAMP CalAmp
$12.25

-0.03 (-0.24%)

03/04/19
ADAM
03/04/19
NO CHANGE
Target $24
ADAM
Buy
CalAmp well positioned to benefit from recurring business model, says Canaccord
Canaccord analyst T. Michael Walkley believes CalAmp is well positioned to drive revenue growth for the next several years with its recurring business model. Walkley reiterated his Buy rating and raised his price target to $24 from $23 on CalAmp shares, citing improving international sales, a growing product portfolio, an increasing list of new customer wins, and accelerating growth of higher margin recurring revenue sales.
01/25/19
JPMS
01/25/19
UPGRADE
Target $17
JPMS
Overweight
CalAmp upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster upgraded CalAmp to Overweight with an unchanged price target of $17. The analyst cites valuation for the upgrade and believes the company's supply chain issues will be resolved in 2019. He sees "solid" execution in the second half of 2019 driving the shares higher.
12/24/18
ROTH
12/24/18
NO CHANGE
Target $23
ROTH
Buy
CalAmp should be bought on any weakness, says Roth Capital
Roth Capital analyst Scott Searle lowered his price for CalAmp to $23 from $24, while reiterating a Buy rating on the shares. The analyst notes that the company reported Q3 results generally in-line with the pre-announcement, with the shortfall attributable to supply chain diversification efforts and European macro weakness. On the positive side of the ledger, Software and Services were slightly better than expected, he adds. Searle recommends using current weakness as a buying opportunity.
03/25/19
JPMS
03/25/19
DOWNGRADE
Target $17
JPMS
Neutral
CalAmp downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded CalAmp to Neutral from Overweight with an unchanged price target of $17. The analyst sees limited catalysts for the shares.

TODAY'S FREE FLY STORIES

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

20:08
12/09/19
12/09
20:08
12/09/19
20:08
Downgrade
Gardner Denver rating change  »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

19:56
12/09/19
12/09
19:56
12/09/19
19:56
Downgrade
Gardner Denver rating change  »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTCWY

Deutsche Wohnen

$0.00

(0.00%)

19:50
12/09/19
12/09
19:50
12/09/19
19:50
Downgrade
Deutsche Wohnen rating change  »

Deutsche Wohnen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

19:49
12/09/19
12/09
19:49
12/09/19
19:49
Downgrade
Segro rating change  »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BORR

Borr Drilling

$6.60

0.46 (7.49%)

19:30
12/09/19
12/09
19:30
12/09/19
19:30
Initiation
Borr Drilling initiated  »

Borr Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$6.89

-0.05 (-0.72%)

19:26
12/09/19
12/09
19:26
12/09/19
19:26
Syndicate
Breaking Syndicate news story on Inseego »

Inseego files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$30.44

16.04 (111.39%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ARQL

ArQule

$19.71

10.035 (103.77%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

XNCR

Xencor

$41.41

0.39 (0.95%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ABR

Arbor Realty

$14.78

(0.00%)

19:20
12/09/19
12/09
19:20
12/09/19
19:20
Syndicate
Arbor Realty 6.5M share Spot Secondary priced at $14.14 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

STRM

Streamline Health

$1.25

-0.04 (-3.10%)

18:59
12/09/19
12/09
18:59
12/09/19
18:59
Hot Stocks
Streamline Health delaying Q3 results to resolve amortization charge »

Streamline Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

, INTC

Intel

$56.52

-0.28 (-0.49%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Periodicals
McAfee weighs combination with NortonLifeLock, WSJ reports »

NortonLifeLock (NLOK) has…

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

INTC

Intel

$56.52

-0.28 (-0.49%)

AVGO

Broadcom

$314.49

-1.68 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 19

    Dec

  • 23

    Jan

TGTX

TG Therapeutics

$9.28

2.17 (30.52%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

NTNX

Nutanix

$33.87

-0.725 (-2.10%)

18:41
12/09/19
12/09
18:41
12/09/19
18:41
Hot Stocks
Nutanix CEO: We are transitioning to a subscription-based model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

  • 16

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

, MDB

MongoDB

$131.03

-0.19 (-0.14%)

18:33
12/09/19
12/09
18:33
12/09/19
18:33
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Stitch…

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

MDB

MongoDB

$131.03

-0.19 (-0.14%)

PHR

Phreesia

$29.01

-0.09 (-0.31%)

CDMO

Avid Bioservices

$5.85

0.05 (0.86%)

MTN

Vail Resorts

$231.30

-1.43 (-0.61%)

TOL

Toll Brothers

$41.40

0.515 (1.26%)

EQ

Equillium

$4.00

-0.03 (-0.74%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

A

Agilent

$81.68

-0.545 (-0.66%)

HEPA

Hepion Pharmaceuticals

$5.61

0.4 (7.68%)

ROAD

Construction Partners

$20.56

0.66 (3.32%)

CASY

Casey's General Stores

$175.33

-0.47 (-0.27%)

CHWY

Chewy

$24.17

-0.76 (-3.05%)

LVGO

Livongo Health

$27.40

-0.6 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

  • 19

    Dec

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32

1.38 (2.30%)

18:24
12/09/19
12/09
18:24
12/09/19
18:24
Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 »

Bluebird bio (BLUE) and…

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

BA

Boeing

$351.25

-2.74 (-0.77%)

18:22
12/09/19
12/09
18:22
12/09/19
18:22
Periodicals
Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says »

An ex-Boeing employee who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:21
12/09/19
12/09
18:21
12/09/19
18:21
Hot Stocks
Occidental Petroleum director buys 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:14
12/09/19
12/09
18:14
12/09/19
18:14
Hot Stocks
Occidental Petroleum director buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EDIT

Editas Medicine

$30.34

-0.6 (-1.94%)

18:02
12/09/19
12/09
18:02
12/09/19
18:02
Hot Stocks
Editas Medicine announces in vivo proof-of-concept data for EDIT-301 »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

, CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

17:56
12/09/19
12/09
17:56
12/09/19
17:56
Hot Stocks
Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs »

The Trustees of Mesabi…

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$24.67

0.12 (0.49%)

17:51
12/09/19
12/09
17:51
12/09/19
17:51
Hot Stocks
First Financial Bancorp chairman Davis sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRE

Green Plains

$14.26

-0.49 (-3.32%)

17:47
12/09/19
12/09
17:47
12/09/19
17:47
Hot Stocks
Green Plains CEO Todd Becker sold over 607K in company shares »

Green Plains CEO Todd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$111.12

-2.02 (-1.79%)

17:43
12/09/19
12/09
17:43
12/09/19
17:43
Hot Stocks
Medtronic director buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

VAC

Marriott Vacations

$123.77

-0.1 (-0.08%)

17:41
12/09/19
12/09
17:41
12/09/19
17:41
Hot Stocks
Marriott Vacations raises quarterly dividend to 54c from 45c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.